The cholinergic hypothesis of Alzheimer's disease: A review of progress

Journal of Neurology Neurosurgery and Psychiatry

Volumn 66, Issue 2, 1999, Pages 137-147

  Francis, Paul T ^a   Palmer, Alan M ^b   Snape, Michael ^b   Wilcock, Gordon K ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Cerebrus Limited   (United Kingdom)

^c FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Acetylcholine; Alzheimer's disease; Cholinesterase inhibitors; Treatment

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; EXCITATORY AMINO ACID; NEUROTRANSMITTER; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ATTENTION; AUTOPSY; BEHAVIOR; BIOCHEMISTRY; BRAIN BIOPSY; CHOLINERGIC SYSTEM; COGNITION; HISTOPATHOLOGY; HUMAN; LEARNING; MEMORY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW;

EID: 0032910197     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.66.2.137     Document Type: Review

References (118)

1. Esiri MM. The basis for behavioural disturbances in dementia. J Neurol Neurosurg Psychiatry 1996;61:127-30.
2. Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99:459-96.
3. Davies P, Maloney AJF. Selective loss of central cholinergic neurones in Alzheimer's disease. Lancet 1976;ii:1403.
4. Perry EK, Gibson PH, Blessed G, et al. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxlyase activities in necropsy brain tissue. J Neurol Sci 1977;34:247-65.
5. Rylett RJ, Ball MJ, Colhuon EH. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. Brain Res 1983;289:169-75.
6. Nilsson L, Nordberg A, Hardy JA, et al. Physostigmine restores [3H]-acetylcholine efflux from Alzheimer brain slices to normal level. J Neural Transm 1986;67:275-85.
7. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurones in basal forebrain. Science 1982;215:1237-9.
8. Drachman DA, Leavitt J. Human memory and the cholinergic system. Arch Neurol 1974;30:113-21.
9. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217: 408-17.
10. Mann DMA. Pyramidal nerve cell loss in Alzheimer's disease. Neurodegeneration 1996;5:423-7.
11. DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 1996;5:417-21.
12. Francis PT, Sims NR, Procter AW, et al. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 1993;60:1589-604.
13. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-9.
14. Wilcock GK, Esiri MM, Bowen DM, et al. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57:407-17.
15. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983;40:503-9.
16. Rossor MN, Garrett NJ, Johnson AL, et al. A postmortem study of the cholinergic and GABA systems in senile dementia. Brain 1982;105:313-30.
17. Lowe SL, Bowen DM, Francis PT, et al. Antemortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 1990;38:571-7.
18. Rossor M. Iversen LL. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br Med Bull 1986;42: 70-44.
19. Francis PT, Bowen DM, Lowe SL, et al. Somatostatin content and release measured in cerebral biopsies from demented patients. J Neurol Sci 1987;78:1-16.
20. Palmer AM, Stratmann GC, Procter AW, et al. Possible neurotransmitter basis of behavioural changes in Alzheimer's disease. Ann Neurol 1988;23:616-20.
21. Chen CPL, Alder JT, Bowen DM, et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlation with depression and neuroleptic medication. J Neurochem 1996;66:1592-8.
22. Bowen DM, Benton JS, Spillane JA, et al. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982;57:191-202.
23. Neary D, Snowden JS, Mann DM, et al. Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry 1986;49: 229-37.
24. Palmer AM, Procter AW, Stratmann GC, et al. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci Lett 1986;66:199-204.
25. Kish SJ, Robitaille Y, El-Awar M, et al. Non-Alzheimer-type pattern of brain choline acetyltransferase reduction in dominantly inherited olivopontinecerebellar atrophy. Ann Neurol 1989;26:362-7.
26. Whitehouse PJ, Martion AM, Marcus KA, et al. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988;45:722-4.
27. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 1992;31:103-11.
28. Warpman U, Alafuzoff I, Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain - alterations in Alzheimer's disease. Neurosci Lett 1993;150:39-43.
29. Chessell IP, Francis PT, Bowen DM. Changes in cortical nicotinic acetylcholine receptor numbers following unilateral destruction of pyramidal neurones by intrastriatal volkensin injection. Neurodegeneration 1995;4:415-24.
30. McCormick DA, Prince DA. Two types of muscarinic responses to acetycholine in mammalian cortical neurones. Proc Natl Acad Sci USA 1985;82:6344-8.
31. Halliwell JV. M-current in human neocortical neurones. Neurosci Lett 1986;67:1-6.
32. Dijk SN, Francis PT, Stratmann GC, et al. Cholinomimetics increase glutamate outflow by an action on the corticostriatal pathway: implications for Alzheimer's disease. J Neurochem 1995;65:2165-9.
33. Hyman BT, Van Hoesen GW, Damasio AR. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 1987;22:37-40.
34. Procter AW, Palmer AM, Francis PT, et al. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 1988;50:790-802.
35. Procter AW, Francis PT, Holmes C, et al. APP isoforms show correlations with neurones but not with glia in brains of demented subjects. Acta Neuropathol 1994;88:545-52.
36. Procter AW. Neurochemical correlates of dementia. Neurodegeneration 1996;5:403-7.
37. Brun A. An overview of light and electron microscopic changes in Alzheimer's disease, the standard reference. New York: Macmillan, 1983:37-47.
38. Lewis DA, Campbell MJ, Terry RD, et al. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease a quantitative study of visual and auditory cortices. J Neurosci 1987;7:1799-809.
39. Rapoport SI, Hatanpaa K, Brady DR, et al. Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Neurodegeneration 1996;5:473-6.
40. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990;27:457-64.
41. Terry RD, Masliah D, Salman N, et al. Psychometrics and their correlation with physical aspects of the Alzheimer's brain. Neurobiol Aging 1990;11:266.
42. Wilcock GK, Esiri MM. Plaques, tangles and dementia. J Neurol Sci 1982;56:343-56.
43. Najlerahim A, Bowen DM. Biochemical measurements in Alzheimer's disease reveal a necessity for improved neuroimaging techniques to study metabolism. Biochem J 1988;251:305-8.
44. Gustafson L, Edvinsson L, Dahlgren N, et al. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychapharmacology 1987;93:31-5.
45. Geaney DP, Soper N, Shepstone BJ, et al. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. Lancet 1990;335:1484-7.
46. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8.
47. Kar S, Issa AM, Seto D, et al. Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem 1998;70:2179-87.
48. Auld DS, Kar S, Quirion R. β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci 1998;21:43-9.
49. Nitsch RM. From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 1996;5:477-82.
50. Emmerling MR, Schwarz RD, Spiegel K, et al. New perspectives on developing muscarinic agonists for treating Alzheimer's disease. ID Research Alert 1997;2:187-94.
51. Clarke NA, Webster M, Francis PT, et al. β-Amyloid precursor protein-like immunoreactivity can be altered in humans by drugs affecting neurotransmitter function. Neurodegeneration 1993;2:243-8.
52. Lovestone S, Reynolds H, Latimer D, et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994;4:1077-86.
53. Sadot E, Gurwitz D, Barg J, et al. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996;66: 877-80.
54. Palmer AM, Gershon S. Is the neurochemical basis of Alzheimer's disease cholinergic or glutamatergic? FASEB 1990;4:2745-52.
55. Andrews JS, Grutzner M, Stephens DN. Effects of cholinergic and non-cholinergic drugs on visual discrimination and delayed visual discrimination performance in rats. Psychopharmacology 1992;106:523-30.
56. Poorheidari G, Stanhope KJ, Pratt JA. Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. Psychopharmacology 1998;135:242-55.
57. Stanhope KJ, McLenachan A, Dourish CT. Dissociation between cognitive and motor/motivation deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists. Psychopharmacology 1995;122:268-80.
58. Dunne MP, Hartley LR. Scopolamine and the control of attention in humans. Psychopharmacology 1986;89:94-7.
59. Warburton DM, Rusted JM. Cholinergic control of cognitive resources. Neuropsychobiology 1993;28:43-6.
60. Hagan JJ, Salamone JD, Simpson J, et al. Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis. Behav Brain Res 1988;27:9-20.
61. Van der Staay FJ, Raaijmakers WGM, Lammers AJJC, et al. Selective fimbra lesions impair acquisition of working and reference memory of rats in a complex spatial discrimination task. Behav Brain Res 1989;32:151-61.
62. Dunnett SB, Everitt BJ, Robbins TW. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci 1991; 14:494-501.
63. Dawson GR, Heyes CM, Iversen SD. Pharmacological mechanisms and animal models of cognition. Behav Pharamacol 1992;3:285-97.
64. Muir JL, Everitt BJ, Robbins TW. AMPA-induced excitotoxic lesions of the basal forebrain - a significant role for the cortical cholinergic system in attentional function. J Neurosci 1994;14:2313-26.
65. 3 receptor antagonist, ondansetron. Psychopharmacology 1995;118:82-92.
66. Sahakian BJ, Coall JT. Nicotine and tetrahydroaminoacridine: evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 1994;31:80-8.
67. Treanor J, Beck K, Hefti F. Neuronal growth factors and Alzheimer's disease. In: Dawbarn D, Allen SJ, eds. Neurobiology of Alzheimer's disease. Bristol: Bios Scientific Publishers, 1995:249-59.
68. Baker HF, Ridley RM. Cholinergic grafts in primates: the role of ACh in cognition. In: Dawbarn D, Allen SJ, eds. Neurobiology of Alzheimer's disease. Bristol: Bios Scientific Publishers, 1995:223-42.
69. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995;18:1145-7.
70. Rogers SL, Yamanishi Y, Yamatsu K. The pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991:314-20.
71. Snape MF, Anderson SMP, Misra A, et al. A comparison of the cholinesterase-inhibitors tacrine and E-2020. Br J Pharmacol 1996;117:P163.
72. Dawson RM. Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci Lett 1990;118:85-7.
73. Moriearty PL, Becker RE. Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL). Methods Find Exp Clin Pharmacol 1992;14:615-21.
74. Sherman KA. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991:321-8.
75. Doraiswamy PM. Current cholinergic therapy for symptoms of Alzheimer's disease. Primary Psychiatry 1996;3:56-68.
76. Homor G, Kasa P. Acetylcholinesterase resynthesis after DFP poisoning: histochemical and biochemical study. Acta Histochem 1978;62:293-301.
77. Taylor P. The cholinesterases. J Biol Chem 1991;266:4025-8.
78. Thomsen T, Zendeh B, Fischer JP, et al. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol 1991; 41:139-41.
79. Sugimoto H, Iimura Y, Yamanishi Y, et al. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors -1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl) methyl]piperidine hydrochloride and related compounds. J Med Chem 1995;38:4821-9.
80. Hunter AJ, Murray TK, Jones JA, et al. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br J Pharmacol 1989;98:79-86.
81. Sussman JL, Harel M, Silman I. 3-Dimensional structure of acetylcnolinesterase and of its complexes with anticholinesterase drugs. Chem Biol Interact 1993;87: 187-97.
82. Harel M, Schalk I, Ehretsabatier L, et al. Quaternary ligand-binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993;90:9031-5.
83. Clarke PBS, Reuben M, Elbizri H. Blockade of nicorinic responses by physostigmine, tacrine and other cholinesterase-inhibitors in rat striatura. Br J Pharmacol 1994;111:695-702.
84. Nilsson L, Adern A, Hardy J, et al. Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine-release in Alzheimer brains via nicotinic receptors? J Neural Transm Suppl 1987;70:357-68.
85. Perry EK, Smith CJ, Court JA, et al. Interaction of 9-amino-1,2,3,4-tetrahydroamino-acridine (THA) with human cortical nicotinic and muscarinic receptor-binding in vitro. Neurosci Lett 1988;91:211-6.
86. 2 muscarine receptors. Neurosci Lett 1988;88: 281-5.
87. Zhu XD, Cuadra G, Brufani M, et al. Effects of MF-268, a new cholinesterase inhibitor, on acetylcholine and biogenic-amines in rat cortex. J Neurosci Res 1996;43: 120-6.
88. Baldwin HA, Desouza RJ, Sarna GS, et al. Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses. Br J Pharmacol 1991;103: 1946-50.
89. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
90. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992;268:2523-9.
91. Knapp JM, Knopman DS, Soloman PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271:985-91.
92. Eagger SA, Harvey RJ. Clinical heterogeneity: responders to cholinergic therapy. Alzheimer Dis Assoc Disord 1995; 9(suppl 2):37-42.
93. Wilcock GK, Scott M, Pearsall T. Long-term use of tacrine [letter]. Lancet 1994;11:567-71.
94. Becker RE, Moriearty P, Unni L. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker RE, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991:263-96.
95. Schneider LS. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 1993;43(suppl 14):S64-79.
96. Rogers SL, Friedhoff ST, and the Donepezil Study Group. The efficacy and safety of donepezil in patients witn Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
97. Rogers SL, Farlow MR, Mohs RC, et al, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
98. Rogers SL, Doody RS, Mohs RC, et al, and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Int Med 1998;158:1021-31.
99. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterse inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
100. Cummings L, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-21.
101. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
102. Knopman DS. Metrifonate for Alzheimer's disease. Is the next cholinesterase inhibitor better? Neurology 1998;50: 1203-5.
103. Fulton B, Benfield P. Galanthamine. Drugs Aging 1996;9: 60-5.
104. Rosen WG, Mohs RC, Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
105. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(suppl 2): S22-32.
106. Friedhoff LT, Rogers SL. Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - results of a preliminary evaluation. Neurology 1997;48:A100(P02.026).
107. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8: 67-75.
108. Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993;31:223-9.
109. Kaufer DI, Catt K, Pollock BG, et al. Donepezil in Alzheimer's disease: relative cognitive and neuropsychiatric responses and impact on caregiver distress. Neurology 1998;50(suppl 4):A89.
110. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-73.
111. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment - effects on nursing-home placement and mortality. Neurology 1996;47:166-77.
112. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA, 1994.
113. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group. Neurology 1984;34:939-44.
114. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-95.
115. Gearing M, Mirra SS, Hedreen JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995;45: 461-6.
116. Folstein NF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
117. Lovestone S, Graham N, Howard H. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997;350:232-3.
118. Anonymous. Alzheimer's disease - drug status update. Current Research in Alzheimer's Disease 1998;3:265-71.